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OBJECTIVES: To examine whether cytomegalovirus
(CMV) and herpes simplex virus type-1 (HSV-1) are asso-
ciated with cognitive decline over a 4-year period and to
assess whether C-reactive protein (CRP) modifies these re-
lationships.
DESIGN: Prospective cohort study over a 4-year period.
SETTING: Community-dwelling elderly population.
PARTICIPANTS: The sample was a subset (1,204/1,789)
of participants in the Sacramento Area Latino Study on
Aging (SALSA) aged 60 to 100.
MEASUREMENTS: Participants were screened annually
over a 4-year period for cognitive function and episodic
memory. Cognitive function was assessed using the mod-
ified Mini-Mental State Examination, and episodic memory
was assessed using a word list-learning test of delayed re-
call. Baseline serum samples were assayed for levels of
immunoglobulin G antibodies to CMV and HSV-1 and for
levels of CRP.
RESULTS: There was a significantly higher rate of cogni-
tive decline over the 4-year period in subjects with the
highest CMV antibody levels at baseline than in individuals
with the lowest levels (b5  0.053, standard error 5
0.018; P 5.003), after controlling for age, sex, education,
income, and chronic health conditions. There was no as-
sociation between HSV-1 antibody levels and cognitive de-
cline. CRP did not modify the relationship between viral
antibody levels and cognitive decline.
CONCLUSION: This is the first study to show that indi-
viduals with higher levels of antibody to CMV experience a
more-rapid rate of cognitive decline than those with lower
levels. Understanding the mechanisms by which CMV in-
fluences cognition may aid development of intervention
strategies targeting infection, viral reactivation, and im-
mune response over the life course. J Am Geriatr Soc
54:1046–1054, 2006.
Key words: herpes; dementia; rate of cognitive decline;
elderly; community
Cognitive impairment and dementia are important caus-es of increased morbidity and mortality in older peo-
ple. As the aging population continues to grow in the United
States, the healthcare needs associated with treating and
caring for elderly individuals with dementia are projected to
pose significant public health and economic burdens.1,2
Researchers agree that it is critical to diagnose dementia at
an early stage to implement prevention efforts and maxi-
mize treatment benefits.3 Studies have implicated biological
inflammatory markers, such as C-reactive protein (CRP)
and cytokines, as predictors of cognitive decline.4–6 Al-
though the identification of such inflammatory markers has
helped unveil the biological pathways that influence de-
mentia risk, limited information is available regarding the
pathophysiological mechanisms that modulate changes in
the level of these markers.
One potential ubiquitous early-life environmental ex-
posure that may act as a proinflammatory factor is latent
infection with herpesviruses, such as cytomegalovirus
(CMV) and herpes simplex virus type 1 (HSV-1). CMV
and HSV-1 are extremely prevalent in older people, and
identification of these viruses in areas of the brain of indi-
viduals affected by Alzheimer’s disease have led to the hy-
pothesis that herpesviruses are causal agents or promoters
of dementia.7 The pathways by which herpesviruses may
influence dementia are not well understood. It is possible
that stress-induced viral reactivation may lead to immune-
related inflammatory cascades and cytokine accumulation,
resulting in direct damage to neurons.8 It has been suggest-
ed that, even when herpesviruses are in a latent state,
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inflammatory processes are ongoing and may be enhanced
by age-related changes in the immune system. For example,
latent CMV has been shown to be highly immunostimula-
tory in older people and is associated with increased CMV-
specific CD81 T-cell proliferation, which may result in
heightened levels of circulating inflammatory cytokines.9
Given the potential pathways between infection, in-
flammation, and cognitive decline, it was hypothesized that
latent viral infections directly influence cognition and that
CRP modulates the relationship between herpesviruses and
cognitive decline. The specific aims of this study were to
examine whether levels of viral antibodies to CMV and
HSV-1 influenced cognitive decline over a 4-year follow-up
period and to assess whether CRP modifies the effect of
viral antibody levels on cognitive decline.
METHODS
Study Population
The participants were derived from the Sacramento Area
Latino Study on Aging (SALSA). SALSA is a large, ongoing,
prospective cohort study of Mexican Americans living in
the community who were aged 60 to 100 at baseline in
1998/99. A subsample of participants (N 5 1,204) from the
overall SALSA cohort (N 5 1,789) with available blood
samples and who had at least two sequential follow-up vis-
its starting from baseline were included in the analyses. The
details of the SALSA study have been discussed previously,
and the institutional review board at the University of
Michigan approved all analyses.10
Study Design
Baseline data collection for the SALSA began in 1998 with a
2-hour interview at participants’ homes. Each year, partic-
ipants were screened for cognitive functioning using the
modified Mini-Mental State Examination (3MSE) and for
episodic memory using a word list-learning test of delayed
recall (DEL-REC).10 Those falling below the education-
and age-adjusted 20th percentile on either of these tests
were referred for further neuropsychological tests, a clinical
examination, and expert adjudication of dementia and cog-
nitive impairment diagnoses. A subsample, including 20%
of subjects with values above the 3MSE or DEL-REC cut-
points, underwent further evaluations aimed at determining
the sensitivity of screening tests, as described elsewhere.10
Lifestyle, health, and demographic factors were collected
annually during the participant interviews. Information on
education, socioeconomic status of the household, medical
history, and duration and date of diagnoses for 35 health
conditions were gathered. Direct clinical evaluations were
used to measure blood pressure and weight/height and
waist/hip ratios.
Laboratory Analyses
The laboratory staff was unaware of the diagnostic classi-
fication of the test samples. A commercially available
enzyme-linked immunosorbent assay (ELISA) immuno-
globulin G (IgG) detection system (Wampole Laboratories,
Princeton, NJ) was used to analyze the level (expressed as
optical density units) of IgG reactive to HSV-1 and CMV in
aliquots of continuously frozen ( 701C) serum samples.
Following manufacturer instructions, samples were as-
sessed for the level of IgG antibody signal as expressed by
the mean optical density value. The sensitivity and
specificity of the assay for HSV-1 are reported to be
97.1% and 96.8%, respectively, and for CMV, the sensi-
tivity and specificity are reported to be 96.4% and 93.3%,
respectively. Each 96-well commercial ELISA kit contained
controls and internal calibrations.
CRP was analyzed using the CRP Ultra Wide Range
Reagent Kit latex-enhanced immunoassay (Equal Diagnos-
tics, Exton, PA). This is a widely used in vitro diagnostic test
for the quantitative determination of CRP in human serum.
Manufacturer’s instructions were followed, and CRP levels
were determined using an automated analyzer and a pre-
pared calibration curve. Using the highly sensitive method,
the kit provides a range of measurable CRP from 0.05 mg/L
to 80.0 mg/L. Results greater than 80.0 mg/L were diluted,
retested, and multiplied by the dilution factor.
Statistical Analyses
For descriptive demographic variables shown in Tables 1
and 2, t tests were used to compare means, and chi-square
or Fisher exact tests to compare proportions. Mixed models
were used to estimate the effect of viral antibody levels
measured at baseline on changes in cognitive functioning
over a 4-year period.11 The measures of cognitive function-
ing were the 3MSE and DEL-REC scores at baseline and
each of a maximum of four follow-up measurements. Be-
cause the distribution of 3MSE scores was negatively
skewed, a natural logarithmic transformation was applied
to this outcome to meet the model assumption of normal-
ity.12 All models presented with 3MSE as the outcome used
the transformed version of this measure. In addition, meas-
ured CRP levels in mg/L were skewed and were therefore
log transformed (lnCRP) to maintain a normal distribution.
In the initial mixed-model analysis, the independent
influence of several potential covariates that have been
identified as risk factors for dementia was explored.13 These
covariates were age, sex, education, income, number of
health conditions reported at baseline (diabetes mellitus,
hypertension, myocardial infarction, angina pectoris, heart
failure, atrial fibrillation, rheumatic fever/heart valve prob-
lem, cancer, and stroke), smoking, body mass index, CRP
levels, Center for Epidemiologic Studies Depression Scale
scores,14 and hetero- or homozygosity for apolipoprotein E-
4 genotype (ApoE-4). Each covariate was assessed in re-
peated-measures mixed models representing decline in
3MSE. In addition, the relationship between each of these
potential covariates and the main predictor variables (i.e.,
baseline CMV and HSV-1 antibody levels) were examined
using linear regression analyses. Consistent with cutoffs
commonly used in the epidemiological literature, only co-
variates that were significantly associated with baseline
cognitive scores at a5 0.05 level and with cognitive decline
(i.e., covariate by time) at a5 0.10 level were included. The
covariates that exhibited statistical significance using these
criteria were age, sex, education, income, and number of
health conditions at baseline.
Modifications were made to the mixed-model covari-
ance structure to obtain better fitting models, as indicated
by a lower Akaike Information Criterion. Based on the
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modifications, all models presented assumed a first-order
auto-regressive covariance structure for the within-subject
error and contained a random intercept allowing variation
in baseline measures of cognition. Also, to account for the
curvilinear pattern of change in cognitive functioning over
time as measured using the 3MSE, all models for this out-
come contained a quadratic term representing the year
(time) of cognitive test scores. Mixed models are presented
in two forms: (1) treating CMV and HSV-1 antibody values
as continuous variables, which assumes a linear relationship
between viral IgG antibody levels and decline in cognition
over time, and (2) a transformation of CMV and HSV-1
antibody values into quartiles, where the first quartile is
considered the referent group for comparison with the sec-
ond, third, and fourth quartiles of viral antibody levels. This
form of the model allows an assessment of potential non-
linear relationships and provides a means of assessing a
dose–response effect of viral antibody levels on rate of cog-
nitive decline. Details on the application of mixed models to
cognitive decline have been described previously.15
The unadjusted mixed models for assessing the rela-
tionship between viral antibody level and cognitive decline
included a term for the viral antibody value, time (since
baseline), and the interaction of the viral antibody value
with year. The next model (initial model) contained the
same variables as the unadjusted model with the addition of
age and sex and their interaction with time. The final mod-
els contained all of the variables in the initial model along
with all other significant covariates (education, income, and
number of baseline health conditions).
To examine whether lnCRP modified the effect of viral
antibody levels on global cognitive decline (3MSE), unad-
justed and adjusted mixed models with three-way interac-
tion terms were fitted. For example, the unadjusted effect
modification model for CMV and lnCRP included the fol-
lowing terms: CMV (antibody levels as a continuous value),
CRP, time, CMV by time, lnCRP by time, lnCRP by CMV,
and CMV by CRP by time. Analyses were conducted using
SAS Version 9.1 (SAS Institute, Inc., Cary, NC) with the




The demographic characteristics of subjects who were in-
cluded in the analyses (N 5 1,204) are shown in Table 1.
Using the clinical cutpoint designated by the ELISA test kits,
97% of the study subjects showed signs of prior infection
with CMV, and 98% showed signs of prior infection with
HSV-1 (Table 2). Levels of CMV IgG antibodies were sig-
nificantly higher in women than men (both Po.001), but
there was no significant difference in levels of HSV-1 (Fig-
ure 1). Most of the participants had CRP levels that have
been considered to indicate high risk for cardiovascular
conditions; CRP levels varied by sex.16 There were signif-
icant, but modest, linear associations between antibody
levels of HSV-1 and CMV (b5 0.147, Po.001), and CMV
Table 1. Descriptive Statistics for the Sacramento Area La-
tino Study on Aging Cohort Analysis Sample (N 5 1,204)
Characteristic Value
Age at baseline, mean  SD 70.3  6.8
Female, % 58
Place of birth Mexico or other
Latin American country, %w
46.3
Number of baseline health
conditions, mean  SD
1.3  1.1









3MSE score, mean  SD (median)k
Baseline 85.7  13.0 (89)
Follow-up year 1 85.4  15.2 (90)
Follow-up year 2 89.6  11.4 (93)
Follow-up year 3 88.9  12.5 (93)
Follow-up year 4 87.1  15.5 (92)
DEL-REC score, mean  SDz
Baseline 8.6  3.1
Follow-up year 1 8.0  3.3
Follow-up year 2 8.8  2.6
Follow-up year 3 7.9  2.8
Follow-up year 4 8.7  3.1
The mean age of the analysis sample was significantly younger than of those
excluded (76.4 vs 77.3, P 5.01).
wA smaller percentage of individuals in the analysis sample were born in Mexico
than of those excluded (46.3% vs 60.7%, Po.001).
z Information on apolipoprotein-E4 status was not available for 80 individuals.
§ Education and income levels of the analysis sample were significantly higher
than of those excluded (all Po.001).
kFor Modified Mini-Mental State Examination (3MSE) scores, the mean and
median are presented, because these values were not normally distributed. In-
dividuals in the analyses sample had significantly higher 3MSE scores at baseline
(Po.001) and at Year 3 (P 5.04) than those excluded.
zDelayed Recall Word List (DEL-REC), scores were significantly higher in the
analysis sample at baseline (Po.001) and Year 4 (P 5.04) than for those ex-
cluded.
SD 5 standard deviation.
Table 2. Proportion Seropositive for Cytomegalovirus
(CMV) and Herpes Simplex Virus Type-1 (HSV-1) and








Virus immunoglobulin G antibody levels
CMV 97.56 95.26 96.59
HSV 98.57 97.63 98.17
CRP levels (mg/L)w
Low (o1) 12.63 25.69 18.12
Medium (1–3) 26.40 33.20 29.26
High (43) 60.98 41.11 52.62
Based on enzyme-linked immunosorbent assay clinical cutpoints for sero-
positivity.
wCutpoints based on Centers for Disease Control and Prevention and the Amer-
ican Heart Association.16
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and lnCRP (b5 0.113, Po.023), controlling for age, sex,
and number of health conditions. There was no significant
linear association between lnCRP and HSV-1 antibody lev-
els (b5 0.050, P4.26).
Viral Antibody Levels and Rate of Cognitive Decline
A one-unit increase in CMV IgG antibody level was asso-
ciated with a significant decline in 3MSE score over the 4-
year period (b5 0.274, standard error 5 0.023;
Po.001) controlling for age, sex, education, income, and
chronic health conditions. This same trend was observed
for the quartile analyses. Tables 3 and 4 show the initial and
final mixed-model effect estimates for quartiles of viral an-
tibody levels on annual rate of cognitive decline as meas-
ured using the 3MSE at each of the five yearly assessments
(i.e., baseline, Year 1, Year 2, Year 3, Year 4). As denoted by
the significant follow-up-time parameter estimates in Ta-
bles 3 and 4, subjects showed an increase in 3MSE scores
over the 4-year study period, indicating a moderate 3MSE
practice effect over time.
Individuals with CMV antibody levels in the upper
quartiles (4th and 3rd) had a more rapid rate of cognitive
decline over the 4-year period than individuals in the lowest
category of CMV antibody levels (1st quartile), controlling
for all covariates (age, sex, education, income, and health
conditions). There was an increase in the magnitude of the
difference, with each quartile compared with the referent
group.
In contrast to CMV, the HSV-1 antibody levels did not
significantly influence rate of cognitive decline over the 4-
year period (Table 4). In addition, neither CMV nor HSV-1
antibody levels were significantly associated with baseline
DEL-REC scores in final models (data not shown, all
P4.05) or declines in the DEL-REC over the 4-year period
(data not shown, all P4.10).
Effect Modification by CRP on Cognitive Decline
There was no significant interaction between increased viral
antibody levels and lnCRP on rate of cognitive decline (i.e.,
CMV by lnCRP by time), controlling for age, sex, health
conditions, education, and income (Table 5). In the final
effect-modification model for CMV, the relationship be-
tween higher CMV antibody levels and rate of cognitive
decline (CMV by time) remained significant, regardless of
the inclusion of variables representing lnCRP, its interaction
with time, the lnCRP-by-CMV interaction, the three-way
interaction term (lnCRP by CMV by time), and covariates.
Effect modification with DEL-REC scores as an outcome
was not assessed, because neither CMV nor HSV-1 was
independently associated with decline in these test scores in
final models.
DISCUSSION
This was the first study to examine the relationship between
herpesvirus antibody levels and rate of cognitive decline
over a 4-year period in community-dwelling elderly indi-
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Figure 1. Quartile distribution of cytomegalovirus (CMV) and
herpes simplex virus type 1 (HSV-1) immunoglobulin G (Ig6)
antibody values. The box-plots show the IgG antibody optical
density units as measured using enzyme-linked immunosorbent
assay.
Table 3. Relationship Between Cytomegalovirus (CMV) Antibody Level and Cognitive Decline
Parameter
Model 1 Model 2w
Mixed-Model b Effect Estimate (Standard Error)
Time 0.324 (0.037)z 0.302 (0.025)z
CMV quartile
4  0.019 (0.057) 0.098 (0.057)
3  0.164 (0.057)§ –0.023 (0.056)
2  0.037 (0.056) 0.036 (0.055)
1 Reference F
Interaction between CMV quartile and time
4 by time  0.064 (0.025)k  0.053 (0.018)k
3 by time  0.043 (0.025)k  0.037 (0.017)k
2 by time  0.021 (0.025)  0.013 (0.017)
1 by time Reference F
Note: Results compare the effect of each quartile of CMV immunoglobulin G antibody level with the lowest quartile (1) on Modified Mini-Mental State Examination
scores over the 4-year period.
Adjusted for age, sex, and their interaction with time.
wAdjusted for age, sex, their interaction with time, education, income, and number of baseline health conditions.
Po z .001; § .05; and k.10 for interaction terms.
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study include the rigorous, widely accepted, standardized
methods for ascertaining cognitive functioning; assessment
and control of numerous potential covariates; and use of a
prospective study design and population-based cohort. In
addition, mixed-model analyses were used to assess poten-
tial dose–response relationships and to model correspond-
ing trajectories of cognitive decline over a 4-year period.
The results suggest that high CMV IgG antibody levels are
an important marker of cognitive decline in older people,
even after controlling for major risk factors such as age,
education, sex, and chronic health conditions. A dose–re-
sponse relationship was observed in which each increase in
quartile of CMVantibody level resulted in a more rapid rate
of cognitive decline. The general inflammatory marker CRP
in the study population did not modify this relationship.
CMV and Cognitive Decline
The findings of an association between high CMV IgG an-
tibody levels and cognitive decline are consistent with one
previous epidemiological study that identified a relationship
between herpesvirus coinfection and cognitive impairment
in elderly Finnish patients with underlying vascular dis-
ease.17 The study showed that Finnish subjects who tested
positive for serum antibodies to CMV, HSV-1, and HSV-2
at baseline had twice the risk of decline in cognitive func-
tioning scores after 1 year as those who did not test pos-
itive.17 Exposure status was measured according to the
presence or absence of IgG antibodies to each virus and
combined seropositivity. The use of seropositivity (i.e., pos-
itive or negative for CMVor HSV IgG antibodies or both) as
a predictor can result in small comparison groups of non-
exposed individuals, given the high prevalence of prior in-
fection with HSV-1 and CMV in the general population.18–
20 The use of seropositivity status as an exposure variable
has been shown to result in instability of regression esti-
mates due to random variability from small cell sizes and
residual confounding.18 In contrast to the previous study,17
the current study used antibody levels as continuous and
quartile-transformed exposure measures to assess linear
and potential dose–response relationships, as well as to
overcome analytical limitations associated with extremely
prevalent predictor variables. The findings regarding CMV
Table 4. Relationship Between Herpes Simplex Virus Type 1 (HSV-1) Antibody Level and Cognitive Decline
Parameter
Model 1 Model 2w
Mixed-Model b Effect Estimate (Standard Error)
Time 0.299 (0.038)z 0.278 (0.026)z
HSV-1 quartile
4  0.111 (0.056) 0.026 (0.056)
3  0.078 (0.056) 0.013 (0.056)
2  0.094 (0.056)  0.012 (0.056)
1 Reference F
Interaction between HSV-1 quartile and time
4 by time  0.018 (0.025) 0.003 (0.017)
3 by time 0.013 (0.025) 0.011 (0.018)
2 by time 0.021 (0.025) 0.010 (0.017)
1 by time Reference F
Note: Results compare the effect of each quartile of HSV-1 immunoglobulin G antibody level with the lowest quartile (1) on Modified Mini-Mental State Examination
scores over the 4-year period.
Adjusted for age, sex, and their interaction with time.
wAdjusted for age, sex, their interaction with time, education, income, and number of baseline health conditions.
z Significant at Po.001.
Table 5. Effect Modification by Log10 C-Reactive Protein (lnCRP) on Cognitive Decline (3MSE Score)
Parameter (Quartile)
Model 1 Model 2w
Mixed-Model b Effect Estimate (Standard Error)
Effect modification of CMV by lnCRP on cognitive decline
CMV by time  0.014 (0.003)z  0.010 (0.003)z
CMV by lnCRP by time 0.001 (0.003) 0.001 (0.003)
Effect modification of HSV-1 by lnCRP on cognitive decline
HSV-1 by time  0.003 (0.004)  0.002 (0.004)
HSV-1 by lnCRP by time  0.001 (0.003) 0.001 (0.003)
Adjusted for time, time by time, virus (CMV or HSV-1), lnCRP, virus by lnCRP, virus by time, lnCRP by time, and virus by lnCRP by time.
wAdjusted for all variables in Model 1 plus age, sex, education, income, and number of baseline health conditions.
Results represent a one-unit increase in herpes virus immunoglobulin G antibody levels (measured in optical density units) on modified Mini-Mental State Ex-
amination (3MSE) scores over the 4-year period.
z Significant at Po.10.
CMV 5 cytomegalovirus; HSV-1 5 herpes simplex virus type 1.
1050 AIELLO ET AL. JULY 2006–VOL. 54, NO. 7 JAGS
antibody levels and cognitive decline were robust even after
controlling for several significant covariates that have been
identified as risk factors for cognitive decline, including age,
education, and numerous health conditions.
It has been shown that acute symptomatic infection in
elderly hospitalized individuals, such as urinary tract infec-
tion, can trigger transient changes in cognition and atten-
tion, resulting in episodes of delirium.21 These bouts of
delirium are a major risk factor for subsequent functional
decline and dementia diagnoses.22,23 In contrast to acute
systemic infection, CMV is a lifelong latent infection that
generally does not cause clinical symptoms in healthy in-
dividuals.19 It is possible that latent CMV plays a role in
cognitive decline via immune system modulation and asso-
ciated inflammatory cytokine cascades rather than direct
pathological effects attributed to active infection. Novel
research findings have shown that latent CMV infection in
older people is an important component of a set of immu-
nological parameters designated the ‘‘immunological risk
phenotype.’’24 This set of immunological markers, includ-
ing latent CMV infection, high cluster of differentiation
(CD)8 cells, low CD4 cell percentages, and poor T-cell pro-
liferation, is predictive of mortality in healthy elderly indi-
viduals.25
Latent CMV is present in CD341 bone marrow pre-
cursor cells and during differentiation of these precursors,
CMV may chronically stimulate the immune system.26 Sev-
eral studies have now reported that there is large clonal
expansion of CMV-specific CD81 T-cells in older people
and that the expansion of these clones are not a conse-
quence of deteriorating health, comorbidity, or a general
loss of immune control over the virus.9,25,27–30 The expan-
sion of CMV-specific clones reduces the availability of
CD81 T-cell carrying receptors that are specific for path-
ogens or foreign antigens other than CMV, thereby limiting
the capacity of the immune system to mount an efficient
response.31 For example, one study reported that a reduced
immune response to influenza vaccination was observed in
elderly individuals who tested seropositive for latent
CMV.31 Moreover, they showed that high levels of CMV
IgG antibody are strongly correlated with increases in se-
rum cytokines tumor necrosis factor (TNF)-a and interleu-
kin (IL)-6 in older people.31 CMV-specific CD81 T-cells
also have the ability to produce interferon (FN)-g.9 Thus, an
accumulation of CMV-specific CD81 T-cells may lead to
an increase in several circulating inflammatory cytokines,
including TNF-a, IFN-g, and IL-6. This increased chronic
peripheral cytokine concentration and reduced repertoire of
T-cells with specificity for pathogens other than CMV is
likely to influence pathophysiological changes associated
with cognitive impairment and dementia.32
The finding of a dose–response relationship between
CMV IgG antibody levels and cognitive decline is further
evidence for an infection-related immunological pathway.
Research is needed to assess whether cytokines, such as IL-6
and TNF-a, modify the relationship between CMV and
cognitive decline, because these markers may increase with
heightened levels of CD41 CMV-specific T-cells associated
with the aging process.9 Recently, a cross-sectional study
showed a significant association between CMV infection
and frailty that was strongly modified by increased IL-6
levels.33 Their findings suggest that proinflammatory cyto-
kines may be an important modulator of latent CMV in-
fection in older people in relation to declines in physical
functioning.33
HSV-1 and Cognitive Decline
Although a few autopsy-based case-control studies have
reported that HSV-1 deoxyribonucleic acid (DNA) is found
in a higher proportion of the brains of people with Alz-
heimer’s disease than in age-matched controls,34–36 the ma-
jority of these autopsy studies report no association be-
tween the presence of the viral DNA and dementia.37–43
The results of the current study do not support a relation-
ship between HSV-1 and cognitive decline.
Studies have implicated ApoE-4 as a potential suscep-
tibility genotype for infection with various pathogens, in-
cluding HSV-1, human immunodeficiency virus, and
malaria.44 Several case-control studies have indicated that
individuals who are positive for the ApoE-4 allele and for
HSV-1 DNA in the brain have a greater risk of Alzheimer’s
disease than those who are ApoE4 positive but do not have
virus present in the brain or than those without either the
virus or the ApoE-4 allele.38–41 This suggests a potential
interaction between HSV-1 and ApoE-4 and dementia risk.7
It was not possible to identify any studies that have exam-
ined interaction between CMV and ApoE-4 and dementia
risk. As a consequence of the limited sample size of indi-
viduals positive for ApoE-4 (5.7%), there was insufficient
power to explore interactions between E-4 and the viral
antibody markers in this study population. Further research
is needed to assess potential gene–virus interactions with
cognitive decline in large population-based prospective
studies.
Effect Modification of Viral Cognitive Trajectories
According to CRP
Two studies have reported a relationship between high CRP
levels and cognitive decline.4,5 In addition, several research-
ers have reported an association between high CRP and risk
of dementia.45–47 The specific mechanisms by which CRP
influences cognitive impairment are still unclear. In an in
vitro study, CRP has been shown to cause toxicity to neu-
ronal cells,48 and studies have identified circulating CRP in
the brains of people with Alzheimer’s disease.49,50 Although
CRP has been shown to be a more-sensitive marker of bac-
terial than viral infection, it also fluctuates with the clinical
course of several viral infections, including CMV.51,52 Nev-
ertheless, there was no indication of an interaction between
CRP and viral antibody levels on changes in cognitive scores
over the 4-year period in the study population. The asso-
ciation between high CMV antibody levels and rate of de-
cline in 3MSE scores was robust, regardless of the inclusion
of CRP levels in the interaction models. This suggests that
the effect of high CMV antibody levels on rate of cognitive
decline is independent of general inflammatory processes
associated with increased CRP. Further study on the patho-
physiological pathways by which CMV influences cognitive
decline is warranted.
Limitations
There are potential limitations associated with use of viral
antibodies as a marker. For example, high levels of herpes-
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virus IgG antibodies may indicate recent primary infection,
but this is unlikely in the study population, because infec-
tion with HSV-1 and CMV commonly occurs at young ages.
(Eighty percent to 90% of elderly populations are infect-
ed.)19,20 There are few data assessing CMV infection in
population-based studies of older Mexican Americans. The
studies that are available have been conducted in Mexican
Americans in other age ranges.53,54 These studies generally
report a higher prevalence of CMV infection in Mexican
Americans than in non-Hispanic whites. The prevalence of
prior infection with HSV-1, which is a virus that is similar to
CMV in terms of transmission, exposure, and latency prop-
erties, has been shown to be significantly higher in U.S.
Hispanics aged 60 and older than in non-Hispanic whites
participating in the National Health and Nutrition Exam-
ination Survey III.20 The seropositivity estimates for HSV-1
observed in the current study are consistent with these na-
tionally representative prevalence estimates of HSV-1 in
Hispanic individuals aged 60 and older.
Given that the prevalence of CMV infection is found to
be higher in Mexican Americans, it is also possible that
reactivation and reinfection may be more common over the
life-course. Such a pattern of infection and reactivation
could lead to an increase in circulating levels of inflamma-
tory cytokines as an adult. CMV has been shown to induce
IL-6 and TNF-a from macrophages and microglial cells.55
Information was not available on levels of inflammatory
cytokines to assess potential correlations with high CMV
antibody levels. Further studies of proinflammatory cyto-
kines as modulators of latent CMV infection in older people
in relation to cognitive decline are warranted.
There are some data indicating that Latino individuals
experience a higher burden of Alzheimer’s disease and an
earlier onset of symptoms,56–58 although it has been diffi-
cult to make conclusions regarding these findings because of
differences in ethnic composition of Latino groups and be-
cause of the potential for ascertainment and selection biases
in racial/ethnic comparative studies.59,60 Further research is
needed to assess whether latent infection and increased
burden of inflammatory cytokines may explain the ob-
served higher rates of cognitive decline in Latinos than in
non-Latino whites, while taking into consideration varia-
bility in ethnic composition within study groups.
Prior HSV-1 and CMV infection are patterned by ed-
ucation and income.19,20 There was a significant associa-
tion between education and income and high CMV and
HSV-1 antibody levels in the SALSA participants. Age and
education were also significant predictors of cognitive de-
cline. Therefore, age and education and their interaction
with time were controlled for in all final models of cognitive
decline. The education and income distribution of the SAL-
SA participants was relatively homogenous, with most in-
dividuals reporting 4 to 11 years of education and an
income of less than $1,000 per month.
Several factors have been identified as initiators of re-
activation of latent herpesviruses, including age, chronic
health conditions, depression/psychosocial stress, and ex-
posure to ultraviolet light.61–66 Of these factors, age, chron-
ic conditions, and depression/psychosocial stress have been
linked to cognitive decline in older people.67,68 Corre-
spondingly, the statistical analyses identified age and chron-
ic health conditions as factors that were associated with
higher CMV antibody levels and were also predictive of
cognitive decline. Therefore, these variables were con-
trolled for in all of the final models. There is also evidence
that depression/psychosocial stress may influence risk of
dementia through complex sociobiological pathways.68–70
Various markers of psychosocial stress have been correlated
with downregulation of specific markers of cellular immune
functioning, including reactivation of latent CMV infec-
tion.71–73 The assessment of depressive symptoms as a
measure of psychosocial stress in the SALSA participants
was not significantly associated with high CMV IgG anti-
body levels. In addition, depressive symptoms were not as-
sociated with a statistically significant rate of cognitive
decline. These findings are consistent with other stud-
ies.74,75 It has been suggested that depression may be cross-
sectionally associated with cognitive impairment but does
not significantly predict rate of cognitive decline.74,75 It is
possible that psychosocial stress measures other than de-
pressive symptoms may be related to CMV reactivation and
cognitive decline. Further studies are required to examine
whether other measure of psychosocial stress, such as dis-
crimination and absence of social support, influence the
relationship between CMV antibody levels and cognitive
decline.
A few factors may have reduced the ability to detect a
significant association between HSV-1 antibody levels and
cognitive decline and may have also resulted in an under-
estimation of the relationship between CMV and rate of
cognitive decline. For example, the study population
showed a moderate practice effect over the 4-year period,
which led to an annual increase in 3MSE scores. Regardless
of the presence of this practice effect, participants with high
CMV antibody levels showed a significantly faster rate of
cognitive decline. In addition, the analyses were limited to
subjects who had participated in the study for at least 2
years starting from baseline. This resulted in the exclusion
of study participants with higher risk profiles for cognitive
decline, including older age and lower levels of education
and income. Therefore, the analysis subsample most likely
represents participants with generally healthier risk profiles
and may have resulted in underestimation of the relation-
ship between the viral antibody measures and cognitive de-
cline.
It was not possible to examine the relationship between
infection and specific forms of cognitive decline. For ex-
ample, earlier research has shown that CMV DNA is found
in a higher proportion of the brains of people with vascular
dementia than in age-matched controls,35 and several stud-
ies have implicated CMV infection as a risk factor for car-
diovascular disease outcomes.76 Research aimed at
assessing whether CMV antibody titers are specifically re-
lated to risk of cognitive decline associated with vascular
dementia is needed.
CONCLUSION
In summary, this is the first study to suggest that high levels
of antibody to CMV are associated with a more-rapid de-
cline in global cognition in a population-based sample of
elderly individuals in the United States. Because multiple
social and pathophysiological changes most likely influence
cognitive decline, an assessment of several markers and
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varying patterns of these markers, including infection, cel-
lular immune response, inflammatory processes, endocrine
levels, and genetic and social factors will provide the most
insight into mechanisms of cognitive decline in elderly pop-
ulations. The findings reinforce the need for additional
large-scale prospective investigations to determine the in-
fluence of CMV antibody levels on rate of development of
cognitive impairment or dementia, as well as a broader un-
derstanding of the potential mechanisms by which these
viral immune measures may affect cognition. Confirmation
of these findings will enhance understanding of whether
CMV infection is a causative factor and may affect inter-
ventions aimed at targeting infection or viral reactivation
over the life-course.
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